World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
54
Citations
10454
World Ranking
3895
National Ranking
342

Overview

Mark R. Wills is affiliated with the University of Cambridge in the United Kingdom. Their research primarily focuses on the fields of Medicine and Immunology and Microbiology, with significant contributions to several subfields including Infectious Diseases, Epidemiology, Immunology, Neurology, and Molecular Biology.

The research topics covered by Mark R. Wills include:

  • SARS-CoV-2 and COVID-19 Research
  • Cytomegalovirus and herpesvirus research
  • COVID-19 Clinical Research Studies
  • Long-Term Effects of COVID-19
  • Immune Cell Function and Interaction
  • Herpesvirus Infections and Treatments
  • HIV Research and Treatment

Recent papers by Mark R. Wills include:

  • Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease, 2021, Immunity
  • SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies, 2021, bioRxiv (Cold Spring Harbor Laboratory)
  • Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial, 2020, The Lancet
  • The CD4+ T Cell Response to Human Cytomegalovirus in Healthy and Immunocompromised People, 2020, Frontiers in Cellular and Infection Microbiology
  • Spontaneous, persistent, T cell-dependent IFN-γ release in patients who progress to Long Covid, 2024, Science Advances

Mark R. Wills frequently collaborates with several researchers including:

  • John Sinclair
  • John R. Bradley
  • Paul Lyons
  • Kenneth G. C. Smith
  • Sarah Jackson

The most common publication venues for Mark R. Wills are:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cell Reports
  • SSRN Electronic Journal
  • Frontiers in Cellular and Infection Microbiology
  • Frontiers in Immunology

Best Publications

  • The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL.

    M. R. Wills;A. J. Carmichael;K. Mynard;X. Jin

  • Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2.

    Dami A Collier;Dami A Collier;Isabella A T M Ferreira;Prasanti Kotagiri;Rawlings P Datir;Rawlings P Datir

  • Ribosome Profiling Reveals Pervasive Translation Outside of Annotated Protein-Coding Genes

    Nicholas T. Ingolia;Gloria A. Brar;Noam Stern-Ginossar;Michael S. Harris;Michael S. Harris

  • Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.

    Dami A. Collier;Dami A. Collier;Anna De Marco;Isabella A. T. M. Ferreira;Bo Meng

  • Functional Heterogeneity and High Frequencies of Cytomegalovirus-Specific CD8+ T Lymphocytes in Healthy Seropositive Donors

    Geraldine M. A. Gillespie;Mark R. Wills;Victor Appay;Chris O'Callaghan

  • Human cytomegalovirus immunity and immune evasion.

    Sarah E. Jackson;Gavin M. Mason;Mark R. Wills

  • Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease.

    Laura Bergamaschi;Federica Mescia;Lorinda Turner;Aimee L. Hanson

  • Identification of Naive or Antigen-Experienced Human CD8 + T Cells by Expression of Costimulation and Chemokine Receptors: Analysis of the Human Cytomegalovirus-Specific CD8 + T Cell Response

    Mark R. Wills;Georgina Okecha;Michael P. Weekes;Maher K. Gandhi

  • The Memory Cytotoxic T-Lymphocyte (CTL) Response to Human Cytomegalovirus Infection Contains Individual Peptide-Specific CTL Clones That Have Undergone Extensive Expansion In Vivo

    Michael P. Weekes;Mark R. Wills;Kim Mynard;Andrew J. Carmichael

  • HUMAN VIRUS-SPECIFIC CD8+ CTL CLONES REVERT FROM CD45ROHIGH TO CD45RAHIGH IN VIVO : CD45RAHIGHCD8+ T CELLS COMPRISE BOTH NAIVE AND MEMORY CELLS

    M. R. Wills;A. J. Carmichael;M. P. Weekes;K. Mynard

  • Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity.

    Mair Thomas;Jessica M Boname;Sarah Field;Sergey Nejentsev

  • CMV and Immunosenescence: from basics to clinics

    Rafael Solana;Raquel Tarazona;Allison E Aiello;Arne N Akbar

  • Human Cytomegalovirus Encodes an MHC Class I-Like Molecule (UL142) That Functions to Inhibit NK Cell Lysis

    Mark R. Wills;Omodele Ashiru;Matthew B. Reeves;Georgina Okecha

  • Human CD28−CD8+ T Cells Contain Greatly Expanded Functional Virus-Specific Memory CTL Clones

    M. P. Weekes;A. J. Carmichael;M. R. Wills;K. Mynard

  • Rapid CD8+ T Cell Repertoire Focusing and Selection of High-Affinity Clones into Memory Following Primary Infection with a Persistent Human Virus: Human Cytomegalovirus

    Elizabeth K. Day;Andrew J. Carmichael;Ineke J. M. ten Berge;Edward C. P. Waller

  • Impact of SARS-CoV-2 B.1.1.7 Spike variant on neutralisation potency of sera from individuals vaccinated with Pfizer vaccine BNT162b2

    Dami Collier;Anna De Marco;Isabella Ferreira;Bo Meng

  • Large clonal expansions of human virus-specific memory cytotoxic T lymphocytes within the CD57+ CD28- CD8+ T-cell population.

    M. P. Weekes;M. R. Wills;K. Mynard;R. Hicks

  • Latency and reactivation of human cytomegalovirus

    J.G.P Sissons;M Bain;M.R Wills

  • NKG2D Ligand MICA Is Retained in the cis-Golgi Apparatus by Human Cytomegalovirus Protein UL142

    Omodele Ashiru;Neil J. Bennett;Louise H. Boyle;Mair Thomas

  • The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies?

    Mark R Wills;Emma Poole;Betty Lau;Ben Krishna

  • Impaired Natural Killer Cell Phenotype and Function in Idiopathic and Heritable Pulmonary Arterial Hypertension

    Mark L. Ormiston;Chiwen Chang;Lu L. Long;Elaine Soon

  • Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

    S Fidler;W Stöhr;M Pace;L Dorrell

Frequent Co-Authors

John Sinclair
John Sinclair University of Cambridge
Andrew M. L. Lever
Andrew M. L. Lever University of Cambridge
Kenneth G. C. Smith
Kenneth G. C. Smith Walter and Eliza Hall Institute of Medical Research
Rainer Doffinger
Rainer Doffinger University of Cambridge
Paul J. Lehner
Paul J. Lehner University of Cambridge
Paul A. Lyons
Paul A. Lyons University of Cambridge
Barbara J. Graves
Barbara J. Graves University of Utah
John Trowsdale
John Trowsdale University of Cambridge
Gordon Dougan
Gordon Dougan University of Cambridge
Maher K. Gandhi
Maher K. Gandhi University of Queensland

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology opens doors to various healthcare professions, many of which benefit from accelerated and flexible online programs. For those interested in advancing to clinical roles swiftly, accelerated FNP programs offer a fast track to becoming a Family Nurse Practitioner, blending immunology knowledge with patient care expertise.

Individuals without a nursing background can explore 12-month accelerated nursing programs online for non nurses, enabling a quick transition into nursing roles that often intersect with immunology in clinical environments.

For those starting their nursing journey, identifying accessible entry points is crucial. The easiest ABSN program to get into can provide an efficient gateway to a Bachelor of Science in Nursing, facilitating deeper engagement with immunological principles in healthcare settings.

Additionally, easiest LPN programs to get into offer practical nursing education with shorter timelines, making them ideal for those seeking quick entry to roles that support immunology-related patient care.

Best Scientists Citing Mark R. Wills

Trending Scientists